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Figure 1. Diagnostic work-up and staging. aIn addition to PSA level, the decision to biopsy should be made in light of DRE ﬁndings, ethnicity, age, comorbid-
ities, free/total PSA, history of previous biopsy and patient values; bindications for a repeat biopsy after a negative biopsy include a rising PSA, suspicious DRE,
abnormal multi-parametric MRI, atypical acinar proliferation, multifocal high-grade prostatic intraepithelial neoplasia; cbefore repeat biopsy, multi-parametric
MRI is recommended with a view to MRI-guided or MRI-TRUS fusion biopsy. CT, computed tomography; DRE, digital rectal examination; GS, Gleason score;
MRI, magnetic resonance imaging; PET, positron emission tomography; PSA, prostate-speciﬁc antigen; TRUS, trans-rectal ultrasound.
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Figure 2. Treatment algorithms. aAlso suitable for localised/locally advanced disease if patient not suitable for (or unwilling to have) radical treatment; binform patients of pros and cons; cfor men with biochemical
relapse and symptomatic local disease, proven metastases or a PSA doubling time of <3 months; donly use Radium-223 if no visceral metastases. ADT, androgen-deprivation therapy; ChT, chemotherapy; EBRT, exter-
nal-beam radiotherapy; HT, hormonal therapy; PC, prostate cancer; PSA, prostate-speciﬁc antigen; RP, radical prostatectomy; RT, radiotherapy.
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